Company News

  • Reset
GOLDEN, Colo. — September 28, 2023 — PharmaJet®, a company that engineers precision delivery systems that overcome the challenges of vaccines and pharmaceuticals delivery, today announced that its partner, Scancell, has received positive data from the first stage in its Phase 2 clinical study for treatment of patients with unresectable
View
GOLDEN, Colo. — April 18, 2023 —PharmaJet®, a company engineering Precision Delivery Systems™ (PDS) that overcome the challenges of vaccine delivery, today announced that it received a scope expansion and 3-year extension of its multi-year agreement with the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency
View
GOLDEN, Colo. — April 4, 2023 — Results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods will be presented at the World Vaccine Congress 2023 on April 5, 2023 at 5:10 pm ET.
View
GOLDEN, Colo. — March 21, 2023 — PharmaJet®, a company engineering precision delivery systems that may overcome the challenges of nucleic acid vaccine delivery, today announced that its partner, Scancell, a developer of novel immunotherapies for the treatment of cancer and infectious diseases, reported positive results from their Phase 1
View
GOLDEN, Colo. — February 23, 2023 — In a review article recently published in Vaccines Journal (MDPI), Dr. Carmen Ledesma-Feliciano, Scientific Affairs Manager at PharmaJet, referencing over 25 studies, discusses multiple injection delivery methods including PharmaJet’s needle-free precision delivery systems, which enhance the clinical performance of DNA-based vaccines.
View
GOLDEN, Colo. — December 13, 2022 — PharmaJet®, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with
Tags: Cancer, DNA, Stratis
View
GOLDEN, Colo. — September 27, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that their latest research results will be presented at five upcoming conferences in October:
View
GOLDEN, Colo. — September 12, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the Military Health System Research Symposium (MHSRS) on September 13, 2022. The presentation, entitled
View
GOLDEN, Colo. — August 2, 2022 — PharmaJet® , a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that its partner, Scancell, will include needle-free delivery of their Phase 2
View
Menu